Ionis Pharmaceuticals (IONS) Short term Debt (2009 - 2026)

Ionis Pharmaceuticals' Short term Debt history runs 18 years deep, the most recent figure standing at $432.5 million for Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $432.5 million; the TTM figure through Mar 2026 stood at $432.5 million (changed N/A YoY), while the FY2025 annual figure was $431.9 million, changed N/A from the prior year.
• Short term Debt was $432.5 million for Q1 2026 at Ionis Pharmaceuticals, roughly flat from $431.9 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $630.9 million in Q3 2025 to a low of $4.2 million in Q1 2022.
• Historically, Short term Debt has averaged $210.6 million across 5 years, with a median of $44.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Short term Debt sank 92.35% in 2022, then surged 1318.83% in 2025.
• A 5-year view of Short term Debt shows it stood at $5.0 million in 2022, then soared by 791.99% to $44.3 million in 2023, then grew by 0.3% to $44.5 million in 2024, then jumped by 871.39% to $431.9 million in 2025, then increased by 0.13% to $432.5 million in 2026.
• The last three Short term Debt figures came in at $432.5 million (Q1 2026), $431.9 million (Q4 2025), and $630.9 million (Q3 2025), per Business Quant data.